The treatment of psoriasis has evolved greatly in the past two decades; nevertheless, treatment guidelines across the world have not been updated so often. Currently, most guidelines for psoriasis including those by the European consensus, the European Dermatology Forum, the British Association of Dermatologist and the Medicare Merit-based Incentive Payment System, require the evaluation of health-related quality-of life (HRQoL) in relation to classification of disease severity and/or evaluation of response to treatment.1 In all of these guidelines, HRQoL is advocated to be assessed by the Dermatology Life Quality Index (DLQI) that has been developed in the early 1990s. This article is protected by copyright. All rights reserved.
